|
Age, years, median (IQR)
|
57 (54 to 63.5)
|
53.5 (44 to 57.5)
|
|
Female, n (%)
|
16 (94)
|
13 (76.5)
|
|
Disease duration, years, median (IQR)
|
12.5 (6 to 20)
|
10 (6 to 16.5)
|
|
Disease activity in 28 joints (DAS28) score, median (IQR)
|
3.4 (3 to 4.4)
|
2 (1.7 to 2.4)
|
|
Rheumatoid factor-positive, n(%)
|
16 (94)
|
16 (94)
|
|
Anti-citrullinated peptide antibodies-positive, n (%)
|
14 (82)
|
14 (82)
|
|
Methotrexate, n (%)
|
17 (100)
|
17 (100)
|
|
Prednisone ≤5 mg/day, n (%)
|
11 (65)
|
4 (24)
|
|
Leflunomide, n (%)
|
2 (12)
|
3 (18)
|
|
Hydroxychloroquine, n (%)
|
2 (12)
|
4 (24)
|
